Both in Pharmaceuticals
Palvella Therapeutics vs Arcus Biosciences
Over the past year PVLA returned +116.2% and RCUS returned −2.6%; their daily moves had a correlation of 0.32.
PVLA +116.2% RCUS −2.6%Growth of $1, one year, split-adjusted
| Metric | PVLA | RCUS |
|---|---|---|
| Price | $162.28 | $19.31 |
| Market cap | $2.34B | $2.46B |
| Today | +6.11% | +2.12% |
| 1 month | +26.8% | −20.5% |
| 6 months | +24.7% | −25.7% |
| Year to date | +55.0% | −19.0% |
| 1 year | +111.2% | −5.1% |
| Revenue growth (YoY) | — | −74.4% |
| Gross margin | — | 100.0% |
| Net margin | — | −222.0% |
| P/E (TTM) | — | — |
| Price / sales | — | 21.0× |
| Net cash | $250.6M | $601.0M |
| Dividend yield | — | — |
| Volatility (60d) | 48.6% | 64.2% |
| Short % of float | 21.7% | 13.6% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).